Last reviewed · How we verify
TEP
TEP is a therapeutic vaccine that works by stimulating the immune system to produce antibodies against the Epstein-Barr virus.
TEP is a therapeutic vaccine that works by stimulating the immune system to produce antibodies against the Epstein-Barr virus. Used for Burkitt lymphoma, Hodgkin lymphoma, Nasopharyngeal carcinoma.
At a glance
| Generic name | TEP |
|---|---|
| Also known as | Thiethylperazine |
| Sponsor | Immungenetics AG |
| Drug class | Therapeutic vaccine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
This vaccine is designed to induce a cellular immune response against EBV, which is associated with various types of cancer. By stimulating the immune system, TEP aims to prevent or treat EBV-related diseases.
Approved indications
- Burkitt lymphoma
- Hodgkin lymphoma
- Nasopharyngeal carcinoma
Common side effects
- Injection site reaction
- Fatigue
- Headache
Key clinical trials
- Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis? (PHASE2)
- FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers (PHASE2)
- Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room
- Study of a Predictor for Cervix Cancer (NA)
- 68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases (NA)
- Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer (NA)
- Feasibility and Efficacy of GTEP for Birth Trauma (NA)
- Study of the Lived Experience of Patients With Prosthetic Joint Infection, Their Families, and Healthcare Professionals. Development of a Therapeutic Education Program for Patient Care (TEP).
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TEP CI brief — competitive landscape report
- TEP updates RSS · CI watch RSS
- Immungenetics AG portfolio CI